Vaxcyte, Inc. (PCVX) Stock Price & How to Invest
Last updated November 2026
Short answer
PCVX is Vaxcyte, a clinical-stage vaccine developer whose whole value rests on its next-generation pneumococcal conjugate vaccine VAX-31, so investing in it is a bet on that vaccine reaching the market rather than on current sales. In October 2026 VAX-31 met all its primary goals in OPUS-1, the first of three adult Phase 3 trials, and Vaxcyte immediately raised about $1.15 billion. As of November 20, 2026 the stock closed near $56.35, up about 21% year to date. You can buy shares through any brokerage, but understand that it has no product revenue and a stock price that moves sharply on trial readouts and financings.
PCVX stock price
As of 2026-11-20, Vaxcyte, Inc. (PCVX) last closed at $55.39, up 15.9% over the past year. Over the past 52 weeks it has traded between $43.06 and $73.82.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Vaxcyte, Inc.'s investor relations page. Walnut is informational, not investment advice.
PCVX key stats
At $55.39 on November 20, 2026, Vaxcyte, Inc. (PCVX) has a market cap of $8.8B.
- Market cap
- $8.8B
- Price to book
- 3.3
- Beta
- 1.29
Market cap, P/E and yield are measured at the $55.39 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Vaxcyte, Inc. (PCVX)?
The last two weeks for Vaxcyte, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- PCVX closed at $55.39 on November 20, 2026, down 12.6% over the past five trading days (from $63.37).
Vaxcyte, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Vaxcyte, Inc. (PCVX) do?
Vaxcyte, Inc. (Nasdaq: PCVX) is a clinical-stage vaccine company built around a proprietary cell-free protein synthesis platform that it uses to design broad-spectrum conjugate vaccines against bacterial disease. Its lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease in adults, which covers more serotypes than currently marketed shots from Pfizer and Merck. The company fully enrolled its three adult Phase 3 OPUS trials (about 6,191 adults dosed) by Q1 2026. In early October 2026 it reported that VAX-31 met all its primary goals in OPUS-1, the main adult trial run against Pfizer's Prevnar 20 and Merck's Capvaxive. OPUS-2 (VAX-31 given with a seasonal flu vaccine) and OPUS-3 (adults previously vaccinated against pneumococcus) are expected to read out in the first half of 2027, and the company has pointed to a Biologics License Application in the first half of 2028. An infant Phase 2 dose-finding study is enrolled, and earlier candidates such as VAX-A1 sit behind it.
The day after the OPUS-1 result, Vaxcyte announced a financing that closed on October 9, 2026 for about $1.15 billion gross: 8,584,375 shares at $64.00, pre-funded warrants for 400,000 more shares, and $575 million of 1.50% convertible senior notes due 2032. The shares fell about 10% on the announcement. The money is earmarked for the adult and infant VAX-31 trials, manufacturing scale-up and inventory ahead of a potential US adult launch.
The investment picture is still a high-stakes biotech setup: no approved products and therefore no product revenue, with operating losses in the hundreds of millions per quarter. Vaxcyte reported its third quarter on November 4, 2026: a net loss of about $297 million, or $1.99 per share, slightly narrower than the $2.11 analysts expected, with research and development spending of about $270 million. It ended September with about $2.26 billion of cash and investments, or roughly $3.4 billion pro forma for the October financing. As of November 20, 2026 the stock closed near $56.35, up about 21% year to date and 18% over twelve months but down about 7% over the past month, for a market value of roughly $8.9 billion, well below a 52-week high near $90.75. The upside case is that VAX-31 wins share in a pneumococcal vaccine market analysts size at well over $10 billion later this decade; the downside case is a disappointing later readout, a regulatory delay or competitive pressure from entrenched players, any of which could sharply reset the valuation. Walnut is not an investment adviser, and this page is descriptive rather than a recommendation.
What's driving Vaxcyte, Inc. (PCVX)?
1. VAX-31 Phase 3 readouts and filing
The central catalyst is the OPUS Phase 3 program for the 31-valent adult pneumococcal vaccine, fully enrolled with roughly 6,191 adults dosed. The first leg cleared in October 2026, when VAX-31 met all its primary goals in OPUS-1 against Prevnar 20 and Capvaxive. OPUS-2 and OPUS-3 follow in the first half of 2027, infant Phase 2 primary-series and booster data are due by the end of that half, a manufacturing consistency study is planned, and the company has pointed to a BLA filing in the first half of 2028. These remaining steps decide when, and with what label, Vaxcyte has a commercial product.
2. Broader serotype coverage as a wedge
VAX-31 targets 31 serotypes, more than Pfizer's Prevnar 20 or Merck's 21-valent Capvaxive, and a prior Phase 2 result was viewed by some analysts as a strong showing against Prevnar 20. If that breadth translates into a differentiated label, it could support share gains in a large, established adult vaccine category.
3. Platform and pipeline optionality
The company's cell-free protein synthesis platform is meant to be reusable across multiple conjugate and protein vaccines, including an infant pneumococcal program and earlier candidates such as VAX-A1 (Group A Strep), which moved to Stage 2 of its adult Phase 1 study after a safety review, with topline data expected in the second half of 2027. Success with VAX-31 would validate the platform and give the pipeline additional shots on goal beyond the lead asset.
4. Strong balance sheet funding the runway
Vaxcyte held about $2.26 billion of cash and investments at September 30, 2026, down from about $2.44 billion at the end of 2025, and the roughly $1.1 billion of net proceeds from the October 2026 stock, pre-funded warrant and 1.50% convertible note offerings takes that to about $3.4 billion pro forma. That cushion funds the trials and launch build-out and reduces near-term financing risk, even as the company burns several hundred million dollars per quarter (trailing operating cash outflow was about $962 million).
What are the risks to Vaxcyte, Inc. (PCVX)?
Vaxcyte is pre-revenue and unprofitable, so the equity remains highly sensitive to clinical and regulatory outcomes; a weak OPUS-2 or OPUS-3 result, a manufacturing problem or a slower FDA path could sharply cut the valuation even after the OPUS-1 success. The company lost about $1.15 billion over the trailing twelve months and keeps raising capital: the October 2026 financing added roughly 9 million shares and warrants plus $575 million of convertible notes that could convert into more stock, so dilution is an ongoing feature. A BLA is not expected until the first half of 2028, which leaves a long, cash-consuming stretch before any sales. It faces entrenched, deep-pocketed competitors (Pfizer, Merck, GSK and Sanofi) with established commercial and payer relationships that could limit uptake even if VAX-31 is approved. Because valuation is driven almost entirely by future expectations rather than current earnings, the stock can be volatile around data and financing news, as the roughly 10% drop on the October offering and the slide to about $56 by late November showed.
What is the Vaxcyte, Inc. (PCVX) forecast?
10 analysts publish price targets on PCVX, averaging $116.40 as of November 2026, or +110.1% against the $55.39 share price on November 20, 2026. The published targets run from $75.00 to $163.00, a wide spread, and the ratings split 10 buy, 1 hold, 0 sell. Over the last six months there have been 2 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full PCVX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is PCVX a buy or a sell?
We give no verdict on Vaxcyte, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. VAX-31 Phase 3 readouts and filing. The central catalyst is the OPUS Phase 3 program for the 31-valent adult pneumococcal vaccine, fully enrolled with roughly 6,191 adults dosed. The most optimistic published target, $163.00, assumes this works close to its best case.
The case against. Vaxcyte is pre-revenue and unprofitable, so the equity remains highly sensitive to clinical and regulatory outcomes; a weak OPUS-2 or OPUS-3 result, a manufacturing problem or a slower FDA path could sharply cut the valuation even after the OPUS-1 success. The most pessimistic target, $75.00, is roughly what PCVX is worth if this bites instead.
Read the full bull and bear case on PCVX, including what would have to change to break either one. Walnut is not an investment adviser.
Has Vaxcyte, Inc. (PCVX) split its stock?
No. Vaxcyte, Inc. (PCVX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Vaxcyte, Inc. (PCVX) valued?
Market cap, P/E and dividend yield at today's price are in the PCVX key stats above. The business figures below come from Vaxcyte, Inc.'s reported results as of November 2026 and change when it next reports.
- Product revenue (TTM): ~$0 (clinical-stage, no approved products)
- Net loss (TTM): ~$1.15B
- Q3 2026 net loss / EPS: ~$297M / -$1.99 (est. -$2.11)
- Operating cash outflow (TTM): ~$962M
- Cash and investments (Sep 30, 2026): ~$2.26B (~$3.4B pro forma for October raise)
As of November 2026: As a clinical-stage biotech, Vaxcyte has no product revenue and cannot be valued on earnings or standard multiples; its roughly $8.9 billion market cap reflects the probability-weighted value of VAX-31 and the pipeline, and it has drifted lower since the October 2026 offering priced at $64. Analysts' mean price target is about $116, against a $56.35 close on November 20, 2026. Consensus has losses of about $7.87 per share in 2026 and $6.87 in 2027, so per-share dilution from equity and convertible raises stays part of the story until the vaccine sells.
Who competes with Vaxcyte, Inc. (PCVX)?
Large-cap pneumococcal incumbents
Pfizer (Prevnar 20 and Prevnar 13) and Merck (Vaxneuvance and the 21-valent Capvaxive, approved in 2024) dominate the pneumococcal conjugate vaccine market with approved products, established manufacturing and deep payer relationships. They are Vaxcyte's most direct commercial competitors and set the coverage bar VAX-31 must beat.
Broader vaccine majors
GSK and Sanofi are major vaccine developers with global commercial reach and adjacent respiratory and pneumococcal programs. Even where they are not head-to-head today, their scale and pipelines make them credible long-term rivals in the adult vaccine category Vaxcyte is targeting.
Clinical-stage vaccine platforms
Other pre-revenue biotechs pursuing conjugate vaccines or novel platform approaches compete with Vaxcyte for scientific validation, trial talent and investor capital. None has VAX-31's late-stage position in high-valency pneumococcal, but the group represents the broader innovation risk to the platform thesis.
What stocks are similar to Vaxcyte, Inc. (PCVX)?
Other names that sit close to PCVX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Vaxcyte, Inc. (PCVX)
There are three common ways to get PCVX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PCVX sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where PCVX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Vaxcyte, Inc. (PCVX)
PCVX is a well-funded, pre-revenue biotech (about $3.4 billion of pro forma cash after the October 2026 raise) that cleared its first VAX-31 Phase 3 hurdle, so the story now turns on OPUS-2, OPUS-3 and infant data in the first half of 2027, a regulatory filing in 2028 and the cost of building a launch, which keeps it high-variance.
More on Vaxcyte, Inc. (PCVX)
Whether PCVX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PCVX a buy or a sell?, and where the stock could go from here in the PCVX stock forecast.
For income investors, whether PCVX pays a dividend and how the payout looks is covered in does PCVX pay a dividend? And to weigh PCVX against a peer, read the full side-by-side comparisons: PCVX vs PFE and PCVX vs GSK.
Wondering how PCVX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Vaxcyte, Inc.
Ask Walnut's AI anything about PCVX and see how it fits what you own.
FAQ
What does Vaxcyte (PCVX) do?
+
Vaxcyte is a clinical-stage vaccine company that uses a cell-free protein synthesis platform to design broad-spectrum conjugate vaccines against bacterial infections. Its lead program is VAX-31, a 31-valent pneumococcal conjugate vaccine for adults.
Does Vaxcyte have any revenue or profit?
+
No. As of November 2026 Vaxcyte has no approved products and therefore no product revenue, and it is not profitable. It reported a Q3 2026 net loss of about $297 million, after about $284 million in Q2 and $321 million in Q1, and roughly $1.15 billion over the trailing twelve months. It funds itself from cash raised in equity and convertible-note offerings.
What is VAX-31 and why does it matter?
+
VAX-31 is Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate, covering more serotypes than current adult vaccines from Pfizer and Merck. It is the company's most valuable asset, so its Phase 3 OPUS trial results largely drive the investment case.
When are the key VAX-31 data readouts?
+
OPUS-1, the lead adult Phase 3 trial against Prevnar 20 and Capvaxive, read out in early October 2026 and met all its primary goals. OPUS-2 and OPUS-3 results are anticipated in the first half of 2027, infant Phase 2 primary-series and booster data are expected by the end of that half, and the company has pointed to a BLA filing in the first half of 2028.
How much cash does Vaxcyte have?
+
Vaxcyte reported about $2.26 billion in cash, cash equivalents and investments as of September 30, 2026, and about $3.4 billion pro forma once the roughly $1.1 billion of net proceeds from the October 2026 offerings are included. Those offerings sold stock at $64.00, pre-funded warrants and $575 million of 1.50% convertible notes due 2032. Operating cash outflow over the trailing twelve months was about $962 million.
Who are Vaxcyte's main competitors?
+
Its most direct competitors are Pfizer (Prevnar 20 and Prevnar 13) and Merck (Vaxneuvance and the 21-valent Capvaxive). GSK and Sanofi are broader vaccine majors that could compete over the longer term in the adult vaccine market.
What are the biggest risks with PCVX?
+
The main risks are a disappointing OPUS-2 or OPUS-3 readout or regulatory delay, ongoing cash burn and dilution (including potential conversion of the 2032 notes), competition from entrenched, larger vaccine makers, and manufacturing scale-up. Because there are no current earnings, the stock can be volatile around clinical and financing news.
How can I invest in PCVX?
+
PCVX trades on the Nasdaq and can be bought through any standard brokerage account, including one connected to Walnut. Walnut is not an investment adviser, so this information is descriptive and you should do your own research or consult a licensed professional before investing.
What happened in the VAX-31 OPUS-1 trial?
+
In early October 2026 Vaxcyte reported that VAX-31 met all its primary goals in OPUS-1, its lead adult Phase 3 trial, which compared it with Pfizer's Prevnar 20 and Merck's Capvaxive. The company announced a roughly $1 billion financing the same evening (upsized to about $1.15 billion), and the shares fell about 10% the next day on the dilution.
How has PCVX stock performed in 2026?
+
As of November 20, 2026 PCVX closed near $56.35, up about 21% year to date and about 18% over twelve months, for a market cap of roughly $8.9 billion. It has slipped about 7% over the past month and sits below the $64.00 price of the October offering. The 52-week range runs from about $42.40 to $90.75. Past performance does not predict future returns.
How did Vaxcyte do in its latest quarter?
+
For the third quarter of 2026, reported November 4, Vaxcyte posted a net loss of about $297 million, or $1.99 per share, against an analyst estimate of a $2.11 loss. Research and development spending rose to about $270 million from about $210 million a year earlier as the OPUS trials and manufacturing scale-up continued. The company reaffirmed first-half 2027 timing for OPUS-2 and OPUS-3.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Vaxcyte, Inc.'s investor relations page or your broker before making investment decisions.